{"brief_title": "Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis", "brief_summary": "This study is intended to evaluate the potential to relieve the symptoms associated with gastroparesis during 12 weeks of treatment with oral tablets given twice a day of GM-611 5mg, 10mg or placebo to type I or II diabetics who require insulin. Additionally the study will evaluate the safety and tolerability of GM-611 compared to placebo, the levels of GM-611 in the blood, and the possible effect of GM-611 on diabetic control.", "condition": "Gastroparesis", "intervention_type": "Drug", "intervention_name": "GM-611", "criteria": "Inclusion Criteria: Major Inclusion Criteria \u2013 Others Stipulated within the Protocol The study physician must assure you have/are: - Must be at least 18 years of age and have diabetes mellitus requiring insulin, which may be in addition to oral anti-diabetic agents. - At least a three month history of the symptoms of gastroparesis that may include: early satiety (feeling full soon after beginning a meal), persistent fullness (long after eating), abdominal distention or bloating, nausea and vomiting. - No evidence of mechanical gastric obstruction, or other gastric problems since the onset of gastroparesis symptoms. - You may be required to under go a Gastric Emptying Test (GET) procedure. - You must be willing and able to maintain a daily telephone diary and consent to participate in this study. Exclusion Criteria: Major Exclusion Criteria \u2013 Others Stipulated within the Protocol The study physician must assure you do not have/are not: - Prior history of gastric surgery, excluding reflux surgery. - Inability to withdraw from current prokinetic agents (e.g., metoclopramide, erythromycin, others) prior to, and during the study. - Unstable current medical or surgical condition, or a recent history of frequent hospitalizations. - A history of: HIV, recurring infection affecting the gastrointestinal track, cirrhosis, acute or chronic liver disease, active pancreatitis, cholecystitis, psychosis, severe depression, Parkinson\u2019s disease, myopathy, scleroderma, eating disorder, or organ transplant. - Evidence or history of QT-prolongation, or use of drugs that are, or may be associated with QT-prolongation are prohibited. - May not be pregnant, breast-feeding or not using approved methods of contraception. - An allergy or intolerance to macrolide antibiotics (e.g., erythromycin). - Use of any investigational drug within 30 days prior to screening.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00050882.xml"}